Do analysts recommend PRFX or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PRFX or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is PRFX or APVO more profitable?

PainReform's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts rate PRFX or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or BGMS more profitable?

PainReform's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts recommend PRFX or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PRFX or BCAB?

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,517.98%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRFX or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A BioAtla N/A N/A -325.64%

PainReform (PRFX) Competitors

$1.48 -0.07 (-4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 -0.01 (-0.81%)

As of 07:59 PM Eastern

Compare

PRFX vs. CDIO, APVO, BGMS, SNOA, and BCAB

Should you buy PainReform stock or one of its competitors? MarketBeat compares PainReform with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PainReform include Cardio Diagnostics (CDIO), Aptevo Therapeutics (APVO), Cyclacel Pharmaceuticals (BGMS), Sonoma Pharmaceuticals (SNOA), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry.

How does PainReform compare to Cardio Diagnostics?

PainReform (NASDAQ:PRFX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

In the previous week, PainReform had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for PainReform and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.87 beat PainReform's score of 0.44 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
Cardio Diagnostics	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	64.38	-$5.02M	-$736.66	N/A
Cardio Diagnostics	$10K	592.00	-$6.50M	-$3.38	N/A

37.3% of PainReform shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PainReform has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. PainReform's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

PainReform has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

Summary

PainReform beats Cardio Diagnostics on 9 of the 13 factors compared between the two stocks.

How does PainReform compare to Aptevo Therapeutics?

PainReform (NASDAQ:PRFX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, PainReform had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for PainReform and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat PainReform's score of 0.44 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
Aptevo Therapeutics	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

37.3% of PainReform shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PainReform has higher revenue and earnings than Aptevo Therapeutics. Aptevo Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	64.38	-$5.02M	-$736.66	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

PainReform has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

PainReform's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Summary

PainReform beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PainReform compare to Cyclacel Pharmaceuticals?

PainReform (NASDAQ:PRFX) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than PainReform. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 2 mentions for PainReform. Cyclacel Pharmaceuticals' average media sentiment score of 0.57 beat PainReform's score of 0.44 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
Cyclacel Pharmaceuticals	Positive

PainReform's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than PainReform. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	64.38	-$5.02M	-$736.66	N/A
Cyclacel Pharmaceuticals	$750K	6.70	-$3M	-$4.54	N/A

37.3% of PainReform shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PainReform has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market.

Summary

PainReform beats Cyclacel Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does PainReform compare to Sonoma Pharmaceuticals?

PainReform (NASDAQ:PRFX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

37.3% of PainReform shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than PainReform. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 2 mentions for PainReform. PainReform's average media sentiment score of 0.44 beat Sonoma Pharmaceuticals' score of 0.29 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Neutral
Sonoma Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. PainReform's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

Sonoma Pharmaceuticals has higher revenue and earnings than PainReform. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	64.38	-$5.02M	-$736.66	N/A
Sonoma Pharmaceuticals	$14.29M	0.37	-$3.46M	-$2.04	N/A

PainReform has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Summary

PainReform beats Sonoma Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does PainReform compare to BioAtla?

PainReform (NASDAQ:PRFX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, PainReform had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for PainReform and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat PainReform's score of 0.44 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
BioAtla	Very Positive

37.3% of PainReform shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
BioAtla	N/A	N/A	-325.64%

PainReform has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

PainReform has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	64.38	-$5.02M	-$736.66	N/A
BioAtla	$2M	2.95	-$59.61M	-$41.72	N/A

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,517.98%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PainReform and BioAtla tied by winning 7 of the 14 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.35M	$2.95B	$6.47B	$11.73B
Dividend Yield	N/A	1.78%	2.67%	5.56%
P/E Ratio	0.00	18.14	24.43	24.33
Price / Sales	64.38	294.59	503.67	108.33
Price / Cash	N/A	56.09	43.20	54.62
Price / Book	0.06	4.00	10.50	6.82
Net Income	-$5.02M	$75.85M	$3.56B	$337.41M
7 Day Performance	-17.32%	-1.99%	-2.02%	-0.96%
1 Month Performance	-18.68%	-3.48%	0.66%	1.68%
1 Year Performance	-85.20%	18.26%	21.85%	26.88%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.6889 of 5 stars	$1.48 -4.5%	N/A	-84.9%	$1.35M	$20K	N/A	4	Short Interest Increase
CDIO Cardio Diagnostics	0.5728 of 5 stars	$2.15 -8.5%	N/A	-57.4%	$6.36M	$16.57K	N/A	1	Positive News
APVO Aptevo Therapeutics	1.8565 of 5 stars	$5.02 -0.4%	N/A	-94.4%	$6.28M	N/A	N/A	50	Positive News
BGMS Cyclacel Pharmaceuticals	0.7605 of 5 stars	$1.06 -2.8%	N/A	N/A	$5.85M	$750K	N/A	14	Positive News Gap Up
SNOA Sonoma Pharmaceuticals	0.5328 of 5 stars	$1.21 +4.3%	N/A	-67.1%	$5.80M	$14.29M	N/A	180	Positive News Short Interest Increase High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. CDIO, APVO, BGMS, SNOA, and BCAB

How does PainReform compare to Cardio Diagnostics?

Summary

How does PainReform compare to Aptevo Therapeutics?

Summary

How does PainReform compare to Cyclacel Pharmaceuticals?

Summary

How does PainReform compare to Sonoma Pharmaceuticals?

Summary

How does PainReform compare to BioAtla?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. CDIO, APVO, BGMS, SNOA, and BCAB

How does PainReform compare to Cardio Diagnostics?

Does the media favor PRFX or CDIO?

Do analysts recommend PRFX or CDIO?

Which has better valuation and earnings, PRFX or CDIO?

Do institutionals and insiders hold more shares of PRFX or CDIO?

Is PRFX or CDIO more profitable?

Which has more volatility & risk, PRFX or CDIO?

Summary

How does PainReform compare to Aptevo Therapeutics?

Does the media prefer PRFX or APVO?

Do analysts prefer PRFX or APVO?

Do institutionals and insiders hold more shares of PRFX or APVO?

Which has higher valuation and earnings, PRFX or APVO?

Which has more volatility & risk, PRFX or APVO?

Is PRFX or APVO more profitable?

Summary

How does PainReform compare to Cyclacel Pharmaceuticals?

Do analysts rate PRFX or BGMS?

Does the media favor PRFX or BGMS?

Is PRFX or BGMS more profitable?

Which has stronger valuation & earnings, PRFX or BGMS?

Do insiders & institutionals hold more shares of PRFX or BGMS?

Which has more risk & volatility, PRFX or BGMS?

Summary

How does PainReform compare to Sonoma Pharmaceuticals?

Do insiders & institutionals have more ownership in PRFX or SNOA?

Does the media prefer PRFX or SNOA?

Do analysts recommend PRFX or SNOA?

Is PRFX or SNOA more profitable?

Which has stronger valuation and earnings, PRFX or SNOA?

Which has more volatility and risk, PRFX or SNOA?

Summary

How does PainReform compare to BioAtla?

Does the media favor PRFX or BCAB?

Do institutionals & insiders have more ownership in PRFX or BCAB?

Is PRFX or BCAB more profitable?

Which has more volatility & risk, PRFX or BCAB?

Which has higher valuation & earnings, PRFX or BCAB?

Do analysts prefer PRFX or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools